Related Experiment Video
Updated: May 2, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
[2013 update in nephrology]
Sophie de Seigneux1, Patrick Saudan2
1Service de néphrologie, Département des spécialités médicales, HUG, 1211 Genève. sophie.deseigneux@hcuge.ch
Abstract:
Vasopressin antagonists show for the first time a beneficial effect on ADPKD cyst growth and renal function in a large cohort of patients. In ANCA vasculitis, the 18 months follow-up of Rituximab treatment for induction confirms the safety and efficacy of this therapeutic option. Two studies brought some answers to what is the more appropriate intravenous fluid strategy to decrease the incidence of acute kidney injury in critically ill patients. Regarding mortality in dialysed patients, inconclusive results about the use of calcimimetics to decrease cardiovascular mortality have been reported but there is good evidence that hemodiafiltration with high ultrafiltration volume can decrease significantly the mortality in these
Insights
Vasopressin antagonists benefit autosomal dominant polycystic kidney disease (ADPKD) cyst growth. Rituximab is safe and effective for ANCA vasculitis, while hemodiafiltration reduces mortality in dialyzed patients.
Area of Science:
- Nephrology
- Internal Medicine
- Critical Care
Context:
- Autosomal dominant polycystic kidney disease (ADPKD) management.
- Treatment strategies for ANCA vasculitis.
- Acute kidney injury (AKI) prevention in critically ill patients.
- Cardiovascular mortality reduction in dialyzed patients.
Purpose:
- To evaluate the effect of vasopressin antagonists on ADPKD progression.
- To assess the long-term safety and efficacy of Rituximab in ANCA vasculitis.
- To determine optimal intravenous fluid strategies for AKI prevention.
- To investigate interventions for reducing cardiovascular mortality in dialysis patients.
Summary:
- Vasopressin antagonists demonstrated a beneficial effect on cyst growth and renal function in a large ADPKD cohort.
- An 18-month follow-up confirmed Rituximab's safety and efficacy for induction therapy in ANCA vasculitis.
- Evidence suggests hemodiafiltration with high ultrafiltration volume significantly decreases mortality in dialyzed patients, though calcimimetics' role remains inconclusive.
Impact:
- Provides novel therapeutic insights for ADPKD.
- Reinforces Rituximab as a viable treatment for ANCA vasculitis.
- Offers guidance on fluid management to mitigate AKI.
- Highlights effective strategies for improving survival in dialysis patients.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury III: Clinical Manifestations
Nephrotic Syndrome III : Nursing Management

